SCHEMBL1779397

SCHEMBL1779397

CCOC(=O)n1nc(NC(=O)c2ccc(CN3CCCCC3)cc2[N+](=O)[O-])c2cc(C(=O)NC(C)(C)c3ccccc3)sc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.49
BCR P11274 2/20 0.49
LMNA P02545 2/20 0.37
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
HTR1A P08908 2/20 0.34
HTR1D P28221 2/20 0.34
HTR1B P28222 2/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PDE7A Q13946 1/20 0.34
MET P08581 1/20 0.34
ALK Q9UM73 1/20 0.34
CYP2C9 P11712 1/20 0.33
AURKA O14965 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1778929 0.99 ABL1 (0.48) ABL1BCRLMNATP53THRB
SCHEMBL1778748 0.94 ABL1 (0.42) ABL1BCRLMNATP53THRB
SCHEMBL1434063 0.88 ABL1 (0.63) ABL1BCRLMNAKDM4EMAPK1
SCHEMBL1779446 0.87 ALDH1A1 (0.43) LMNATP53THRBKDM4ENPSR1
SCHEMBL1779035 0.85 ABL1 (0.47) ABL1BCRLMNAPDE7AAURKA
SCHEMBL1434583 0.83 ABL1 (0.61) ABL1BCRLMNAKDM4EL3MBTL1
SCHEMBL12603552 0.82 KDM4E (0.37) ABL1BCRTP53KDM4EMAPK1
SCHEMBL1433921 0.82 ABL1 (0.62) ABL1BCRLMNAKDM4EALDH1A1
SCHEMBL1434082 0.82 ABL1 (0.62) ABL1BCRLMNAKDM4EMAPK1
SCHEMBL1897386 0.82 ABL1 (0.59) ABL1BCRLMNAMAPK1PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 ABL1 397/4885BCR 1047/4885LMNA 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.